Merseyside & Cheshire Cancer Network Dashboard

Merseyside & Cheshire
Cancer Network
Dashboard
May 2010.
If you wish to know more about the Cancer Network Dashboard please contact the Merseyside
and Cheshire Cancer Network.
Version2.0 Part 2 Cancer Dashboard MCCN 2010

Background
The National Awareness and Early Detection Initiative-NAEDI- was announced in the Cancer
Reform Strategy (CRS) and is being led by Professor Mike Richards, National Cancer Director
and Harpel Kumar the Chief Executive of Cancer Research UK. Cancer Networks are well placed
to provide leadership for prevention and early diagnosis. Cancer Networks and PCTs are
expected to undertake a baseline assessment that will inform Network and PCT Strategic
Commissioning Plans to ensure effective progress in this area based on local needs.
A Cancer Dashboard
The cancer network have developed performance measures that include baseline measures but
also add further quality to information that is appropriate for PCTs and GP practices and we want
to embed these into a more robust cancer dashboard using and testing measures. We see this as
a way of assessing current baselines within PCTs and also practices but will also enable us to
analyse performance regularly.
The cancer dashboard will be outcome driven; each PCT will be asked to complete a template
with the Early Detection and Awareness Strategy lead team. We will agree milestones with PCTs
and assist them in supporting the gathering of evidence for the individual measures, including
measures by practice. We envisage that action plans will be developed and adopted by PCT
boards as appropriate and recommendations will be made to commissioners, these
recommendations will be more likely to be considered as they will be evidence based. A key
element of the cancer dashboard will be the development of a database that PCTs and practices
can access to review performance and to create reports.
The cancer dashboard will:
Collate primary care equity audits for urgent referrals in the PCT by practice- this will
include, review of referring patterns linked to deprivation, number of referrals, cancer
yield. This is different than the primary care audits.
Capture data within templates for survival, mortality, incidence, screening and staging
data and will identify key trends and variations.
Provide PCT reporting in a template that will demonstrate compliance with national and
local baseline assessments identified within the Cancer Reform Strategy.
Provide information about screening performance at GP practice and PCT level,
templates for GP practices will be made available.
Capture action plans to enable Commissioners to make decisions on services.
Test other performance measures around commissioning such as length of stay analysis
and other commissioning priorities.
We believe that the cancer dashboard will enhance the PCTs ability to demonstrate their
progress on world class commissioning (WCC) and quality, innovation, productivity and
prevention (QUIPP)
Dr Daniel Seddon- Early detection and prevention lead
Paul Mackenzie- Health Inequalities Manager
Version 2 Cancer Dashboard MCCN 2010 2

Baseline key metrics and indicators for the Cancer Dashboard.
No Performance category Network PCT Practice Trust
1. Proportion of diagnosed cancers reaching a 90% registration status (including staging) with
√ √ √
NWCIS after 90 days
2. TWW activity including did not attend (DNA) and cancellation rates √ √ √ √
3. Total number of Urgent 2 week wait referrals by tumour site √ √ √ √
4. Urgent 2 week wait cancer referral yield rate by tumour site (Yield = No of Diagnosis Cancers/
√ √ √
Number of Urgent 2 week wait referrals
5. Number of Urgent 2 week wait cancer referrals by tumour site with a cancer diagnosis √
6. Coverage rates for national bowel cancer screening programme √ √
7. % variation from national coverage rates for bowel cancer screening programme √ √
8. Number of cancers detected as a result of the bowel cancer screening programme √ √
9. % Never screened for bowel cancer √ √
10. Coverage rates for national cervical screening programme √ √
11. % variation from national coverage rates for the cervical screening programme √ √
12. Number of cancers detected as a result of the cervical screening programme √ √
13. % Never screened for cervical cancer √ √
14. % patients receiving cervical screening results within 2 weeks following screening √
15. Lab data
16. Coverage rates for national breast screening programme √ √
17. % variation from national coverage rates for the breast screening programme √ √
18. Number of cancers detected as a result of the breast screening programme √ √
19. % Never screened for breast cancer √ √
20. European Age Standardised Cancer Incidence rates for all cancers compared to the national
√
√
average and best in Europe (if appropriate)
21. European Age Standardised Cancer Mortality rates for all cancers compared to the national
√
√
average and best in Europe (if appropriate)
22. % variation in 1 year relative survival rates for all cancers compared to the national average and √
best in Europe (if appropriate)
23. % variation in 5 year relative survival rates for all cancers compared to the national average and √
best in Europe (if appropriate)
24. Number of emergency admissions resulting in the first definitive cancer diagnosis √ √ √

1. Public awareness of Cancer
The Cancer Awareness Measure has been developed as part of the national awareness and
early detection initiative (NAEDI) to help to ensure the delivery of the Cancer Reform Strategy
(CRS). The survey has been designed to benchmark the current level of awareness amongst the
population. The CAM will serve as a baseline against which we will be able to evaluate
awareness raising initiatives within PCTs.
The CAM is usually a face to face interview or telephone interview
Awareness of cancer signs and symptoms
Help-seeking behaviour
Awareness of risk factors
Awareness of cancer incidence and common cancers
Awareness of cancer screening programmes
Contribution to cancer
Cancer Awareness Measure
1a
Has the PCT conducted a CAM to benchmark local awareness?
Level 1 PCT not aware of the level of knowledge in the local population
Level 2 Plans being developed for 2010/11
Level 3 Some evidence of awareness measurement
Level 4 The PCT can demonstrate baseline measurement of public knowledge of cancer
Level 5
Excellent
CAM measure or equivalent conducted in the PCT. Further evidence of
application to specific groups in society demonstrated.
Self
Evidence summary:
assessment
rating

Public awareness
1b
Has the PCT engaged the public in cancer awareness activity?
Level 1 PCT cannot identify any cancer awareness initiatives in the PCT
Level 2 Plans being developed for 2010/11
Level 3 Some evidence of cancer awareness activity in one or two cancer specific areas
Level 4 The PCT can demonstrate strong community engagement with examples of
cancer awareness activity
Level 5 The PCT has targeted cancer awareness campaigns or activity and is actively
Excellent engaged in developing knowledge and understanding in communities. (e.g.
Health Communities Cancer Collaborative) There are plans to repeat the CAM to
Self
assessment
rating
evaluate increased awareness.
Evidence summary:
Local action plan
How will the PCT identify cancer awareness knowledge in the population and what awareness
campaigns will be targeted?
Action to be taken
Who will lead on the delivery of this action?
Identify milestones
Version 2 Cancer Dashboard MCCN 2010 5

2. Screening
a. Bowel
b. Breast
c. Cervical
Bowel cancer screening
Roll out of the national bowel cancer screening programme has been achieved within Cheshire
and Merseyside. This programme invites most men and women aged 60-69 years. Self referral
was an option during the first phase of roll out. The CRS (2009) second annual report highlights
that 4.5 million kits have been sent out resulting in 17,000 polyp removals and 4,000 cancers
being diagnosed.
The extension of bowel screening to men and women aged 70-75 from 2010 is a Vital Sign in the
NHS Operating Framework (VSA10).
There is currently no national target for bowel screening although pilot studies resulted in around
a 60% coverage rate. There is considerable variation of uptake amongst those in lower socio
economic areas, within different ethnicity and cultures and in those who are no registered with a
GP.
Breast screening
The NHS Breast Screening Programme provides free breast screening every three years for all
women in the UK aged 50 and over. Around one-and-a-half million women are screened in the
UK each year. Women aged between 50 and 70 are now routinely invited.
The NHS Breast Screening Programme will extend the age range of women eligible for breast
screening to ages 47 to 73 by 2012.
The national target for breast screening coverage is 70%.
Cervical screening
All women between the ages of 25 and 64 are eligible for a free cervical screening test every
three to five years. The NHS Cervical Screening Programme now offers screening at different
intervals depending on age. This means that women are provided with a more targeted and
effective screening programme. The national coverage rate is 80%
The new intervals are;
Age Duration
25 First invitation
25 - 49 3 yearly
50 - 64 5 yearly
65+ Only screen those who have not been screened since age 50 or have had recent
abnormal tests
Achieving a 14 day turnaround time for results of cervical screening is a Vital Sign in the NHS
Operating Framework (VSA15). This is to be achieved by the end of 2010.
Version 2 Cancer Dashboard MCCN 2010 6

Operational leadership
2a
Does the PCT have a screening operational and strategic lead in place?
Level 1 The PCT does not have an operational screening lead in place
Level 2 The PCT designates this responsibility to a number of people
Level 3 The PCT has an operational and strategic lead
Level 4 The PCT has an operational and strategic lead and they represent the PCT at a
variety of screening meetings
Level 5
Excellent
The PCT has an operational and strategic lead and they represent the PCT at a
variety of screening meetings. They are actively engaged in the cancer network
Self
assessment
rating
and public health network screening groups
Evidence summary:
Implementation plans
2b
Does the PCT have an implementation plan for screening in place?
Level 1 No plan in place
Level 2 Plans being developed
Level 3 An operational plan is only available for some of the screening programmes
Level 4 A full operational plan is in place and can be shared for all cancer screening
programmes
Level 5
Excellent
A full operational plan is in place and can be shared for all cancer screening
programmes. Action plans and performance is reviewed regularly and shared
Self
assessment
rating
with the PCT board.
Evidence summary:
Version 2 Cancer Dashboard MCCN 2010 7

Breast screening extension
2c
Has the PCT made plans to start the extension of breast cancer screening
offered to women aged 47-49 and 71-73 from April 2010?
Level 1 No plans in place
Level 2 Plans in place
Level 3 Making good progress on plans
Level 4 Breast extension will begin after April 2010
Level 5 Breast extension has begun
Excellent
Self
assessment
rating
Two week reporting cervical screening
2d
Is the PCT reporting the results of cervical screening within two weeks?
Level 1 No plans in place
Level 2 Not able to review data
Level 3 Data reviewed but performance is below expectations 80%
Level 4 90% of 2 week turnaround
Level 5 99% of 2 week turnaround
Excellent
Self
assessment
rating
Bowel cancer screening coverage
2e
How is the PCT achieving the national average coverage rate for bowel
screening? How is the PCT improving coverage rates
Level 1 The PCT overall is not achieving level 2
Level 2 The PCT overall is achieving between at least 50% and 54% coverage with more
than a third of ward areas having more than 50%
Level 3 The PCT overall is achieving between 55% and 59% coverage with more than
two thirds of ward areas having more than 55%
Level 4 The PCT overall is achieving between 60% and 64% coverage with more than
two thirds of ward areas having more than 60%
Level 5 The PCT overall is achieving between 65 and 69% coverage with more than two
Excellent thirds of ward areas having more than 65%
Self
How is the PCT improving screening rates?
assessment
rating
Version 2 Cancer Dashboard MCCN 2010 8

Breast cancer screening coverage
2f
How is the PCT achieving the national average coverage rate breast screening?
How is the PCT improving coverage rates
Level 1 The PCT is not achieving level 2
Level 2 The PCT overall is achieving between 50% and 54% coverage with more than
two thirds of practices having more than 50%
Level 3 The PCT overall is achieving between 60% and 64% coverage with more than
two thirds practices having more than 60%
Level 4 The PCT overall is achieving between 65% and 69% coverage with more than
two thirds of practices having more than 65%
Level 5 All practices in the PCT are achieving 70% coverage or more
Excellent
Self
How is the PCT improving screening rates?
assessment
rating
Cervical screening coverage
2g
How is the PCT achieving the national average coverage rate for cervical
screening? How is the PCT improving coverage rates
Level 1 The PCT is not achieving level 2
Level 2 The PCT overall is achieving between 65% and 69% coverage with more than
two thirds of practices having more than 65%
Level 3 The PCT overall is achieving between 70% and 74% coverage with more than
two thirds of practices having more than 70%
Level 4 The PCT overall is achieving between 75% and 79% coverage with more than
two thirds of practices having more than 75%
Level 5 All practices in the PCT are achieving more than 80% coverage or more
Excellent
Self
assessment
rating
Version 2 Cancer Dashboard MCCN 2010 9

Non participants in screening
2h
How is the PCT identifying which groups in the community are not participating
in screening?
Level 1 The PCT cannot identify the groups
Level 2 The PCT is aware of the different groups who are not taking up screening
Level 3 The PCT identify groups and individuals who do not take up screening
Level 4 The PCT has a system in place to ensure all groups are invited for screening
Level 5 The PCT has a system in place to ensure all groups are invited for screening
Excellent and can demonstrate performance
Self
assessment
rating
How will the PCT improve coverage rates for screening?
Action to be taken
Bowel cancer screening
Breast screening
Cervical screening
Who will lead on the delivery of this action?
Identify milestones
Version 2 Cancer Dashboard MCCN 2010 10

3. Delays in presentation/ Referral
Patient’s survival and mortality is likely to be poorer if they present late to primary care with
potential cancer symptoms. Community engagement projects such as the Healthy Communities
Collaborative and IVAN mobile support and information service can target awareness and prompt
earlier presentation to primary care.
The national audit of cancer diagnosis in primary care is a tool supported by the Royal College of
General Practitioners and the National Cancer Action Team. The tool captures themes in the
patient experience from delay presenting to the GP, through referral and diagnostics. This tool is
a reflective learning tool; each practice reviews the pathway for each audit. Yearly audits like this
have been highlighted as a key recommendation from the All Party Parliamentary Group on
Cancer.
Primary care audits
3a
The PCT can provide evidence of audits that inform the PCT of delays in the
patient experience prior to diagnosis using primary care audits
Level 1 No evidence
Level 2 Plans to participate in audits
Level 3 PCT has been involved in network primary care audit initiative
Level 4 The PCT plans involve at least a third of all practices in collecting audits
Level 5 The PCT has developed an agreement to repeat audits in each practice yearly
Excellent
Self
assessment
rating
Referral under the urgent two week waits (TWW)
3b
The PCT regularly reviews urgent TWW activity including did not attend (DNA)
and cancellation rates
Level 1 The PCT is not at level 2
Level 2 The PCT can demonstrate that it is starting to review TWW data on DNA/
cancellation rates
Level 3 The PCT can extract reports by GP practice to show DNA cancellation rates
Level 4 The PCT can extract reports by GP practice to show DNA cancellation rates and
reviews them at cancer action team meetings. A plan has been developed to
reduce DNA/ cancellation rates. The PCT can demonstrate a reduction in DNA/
Cancellation rates by PCT
Level 5
Excellent
Self
assessment
rating
The PCT can extract reports by GP practice to show DNA cancellation rates and
reviews them at cancer action team meetings. A plan has been developed to
reduce DNA/ cancellation rates. The PCT can demonstrate a reduction in DNA/
Cancellation rates by PCT and by those practice with the worst DNA rates
Version 2 Cancer Dashboard MCCN 2010 11

3c
Level 1
Level 2
Level 3
Level 4
Level 5
Excellent
The PCT regularly reviews TWW activity including yield rates
Does not review urgent rates by practice
Reviews TWW on a ad hoc basis
Reviews TWW and reports findings to PCT
Reviews TWW and provides regular reports on efficiency including yield rates
Reviews TWW data every quarter and reports on efficiency to PCT, GP and
Trust colleagues. Initiatives to improve TWW. Cancer yield rates can be
identified (referrals versus actual cancer diagnosis). Equity audits have been
completed for the PCT
Emergency presentation
3d
The PCT can review cancers that have been diagnosed via accident and
emergency
Level 1 Unable to identify cancers via this route
Level 2 PCT is exploring ways to gather this data
Level 3 PCTs can identify emergency presentations resulting in a cancer diagnosis
Level 4 PCTs can identify emergency presentations resulting in a cancer diagnosis and
this is shared with GP practices
Level 5
Excellent
Self
assessment
rating
PCTs can identify emergency presentations resulting in a cancer diagnosis and
this is shared with GP practices. The reasons for emergency presentation are
being investigated and performance can be measured on a regular basis
How will the PCT improve referrals?
Action to be taken
Who will lead on the delivery of this action?
Identify milestones
Version 2 Cancer Dashboard MCCN 2010 12

4. Staging
The information for the stage of cancer is essential to help a person choose the best treatment. It
also helps them to understand their prognosis.
Cancer Registration
4a
Level 1
Level 2
Level 3
Level 4
Level 5
Excellent
Self
assessment
rating
Bladder
How complete is the clinical stage data for cancers 3 months after registration?
Less than 50% and has a system in place to capture staging data (i.e. Somerset)
50%-59% and has a system in place to capture staging data (i.e. Somerset)
60%-79% and has a system in place to capture staging data (i.e. Somerset)
80%-89% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data
90+% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data in collaboration with the cancer network and
NWCIS
Evidence summary:
4b
Level 1
Level 2
Level 3
Level 4
Level 5
Excellent
Self
assessment
rating
Bladder
How complete is the final stage data for cancers 3 months after registration?
Less than 50% and has a system in place to capture staging data (i.e. Somerset)
50%-59% and has a system in place to capture staging data (i.e. Somerset)
60%-79% and has a system in place to capture staging data (i.e. Somerset)
80%-89% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data
90+% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data in collaboration with the cancer network and
NWCIS
Evidence summary:
Version 2 Cancer Dashboard MCCN 2010 13

4c
Level 1
Level 2
Level 3
Level 4
Level 5
Excellent
Self
assessment
rating
Prostate
How complete is the clinical stage for cancers 3 months after registration?
Less than 50% and has a system in place to capture staging data (i.e. Somerset)
50%-59% and has a system in place to capture staging data (i.e. Somerset)
60%-79% and has a system in place to capture staging data (i.e. Somerset)
80%-89% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data
90+% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data in collaboration with the cancer network and
NWCIS
Evidence summary:
4d
Level 1
Level 2
Level 3
Level 4
Level 5
Excellent
Self
assessment
rating
Prostate
How complete is the final stage data for cancers 3 months after registration?
Less than 50% and has a system in place to capture staging data (i.e. Somerset)
50%-59% and has a system in place to capture staging data (i.e. Somerset)
60%-79% and has a system in place to capture staging data (i.e. Somerset)
80%-89% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data
90+% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data in collaboration with the cancer network and
NWCIS
Evidence summary:
4e
Level 1
Level 2
Level 3
Level 4
Level 5
Excellent
Self
assessment
rating
Colorectal
How complete is the clinical stage for cancers 3 months after registration?
Less than 50% and has a system in place to capture staging data (i.e. Somerset)
50%-59% and has a system in place to capture staging data (i.e. Somerset)
60%-79% and has a system in place to capture staging data (i.e. Somerset)
80%-89% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data
90+% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data in collaboration with the cancer network and
NWCIS
Evidence summary:
Version 2 Cancer Dashboard MCCN 2010 14

4f
Level 1
Level 2
Level 3
Level 4
Level 5
Excellent
Self
assessment
rating
Colorectal
How complete is the final stage data for cancers 3 months after registration?
Less than 50% and has a system in place to capture staging data (i.e. Somerset)
50%-59% and has a system in place to capture staging data (i.e. Somerset)
60%-79% and has a system in place to capture staging data (i.e. Somerset)
80%-89% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data
90+% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data in collaboration with the cancer network and
NWCIS
Evidence summary:
4g
Level 1
Level 2
Level 3
Level 4
Level 5
Excellent
Self
assessment
rating
Malignant Melanoma
How complete is the final stage data for cancers 3 months after registration?
Less than 50% and has a system in place to capture staging data (i.e. Somerset)
50%-59% and has a system in place to capture staging data (i.e. Somerset)
60%-79% and has a system in place to capture staging data (i.e. Somerset)
80%-89% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data
90+% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data in collaboration with the cancer network and
NWCIS
Evidence summary:
4h
Level 1
Level 2
Level 3
Level 4
Level 5
Excellent
Self
assessment
rating
Lung
How complete is the clinical stage for cancers 3 months after registration?
Less than 50% and has a system in place to capture staging data (i.e. Somerset)
50%-59% and has a system in place to capture staging data (i.e. Somerset)
60%-79% and has a system in place to capture staging data (i.e. Somerset)
80%-89% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data
90+% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data in collaboration with the cancer network and
NWCIS
Evidence summary:
Version 2 Cancer Dashboard MCCN 2010 15

4i
Level 1
Level 2
Level 3
Level 4
Level 5
Excellent
Self
assessment
rating
Lung
How complete is the final stage data for cancers 3 months after registration?
Less than 50% and has a system in place to capture staging data (i.e. Somerset)
50%-59% and has a system in place to capture staging data (i.e. Somerset)
60%-79% and has a system in place to capture staging data (i.e. Somerset)
80%-89% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data
90+% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data in collaboration with the cancer network and
NWCIS
Evidence summary:
4j
Level 1
Level 2
Level 3
Level 4
Level 5
Excellent
Self
assessment
rating
Breast
How complete is the clinical stage for cancers 3 months after registration?
Less than 50% and has a system in place to capture staging data (i.e. Somerset)
50%-59% and has a system in place to capture staging data (i.e. Somerset)
60%-79% and has a system in place to capture staging data (i.e. Somerset)
80%-89% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data
90+% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data in collaboration with the cancer network and
NWCIS
Evidence summary:
4k
Level 1
Level 2
Level 3
Level 4
Level 5
Excellent
Self
assessment
rating
Breast
How complete is the final stage data for cancers 3 months after registration?
Less than 50% and has a system in place to capture staging data (i.e. Somerset)
50%-59% and has a system in place to capture staging data (i.e. Somerset)
60%-79% and has a system in place to capture staging data (i.e. Somerset)
80%-89% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data
90+% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data in collaboration with the cancer network and
NWCIS
Evidence summary:
Version 2 Cancer Dashboard MCCN 2010 16

4l
Level 1
Level 2
Level 3
Level 4
Level 5
Excellent
Self
assessment
rating
Haematology – Hodgkin lymphoma
How complete is the final stage data for cancers 3 months after registration?
Less than 50% and has a system in place to capture staging data (i.e. Somerset)
50%-59% and has a system in place to capture staging data (i.e. Somerset)
60%-79% and has a system in place to capture staging data (i.e. Somerset)
80%-89% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data
90+% and has a system in place to capture staging data (i.e. Somerset) and
regularly review staging data in collaboration with the cancer network and
NWCIS
Evidence summary:
MDT performance
4m
Is MDT performance improving?
Level 1 No MDT data submitted
Level 2 MDT data being submitted
Level 3 MDT data submitted for all MDTs
Level 4 MDT data submitted for all MDTs and the quality is reviewed. MDTs have self
assessed themselves. Annual audits can be demonstrated. Data captured for
ethnicity, gender, age and treatment on Somerset Cancer Register or MDT
proforma.
Level 5 MDT data submitted for all MDTs and the quality is reviewed. With 90% of data
Excellent sets completed. MDTs have self assessed themselves. MDT completes annual
audits and can demonstrate that it can capture stage, ethnicity, gender, age and
Self
assessment
rating
treatment
Evidence summary:
How will the PCT improve MDTs?
Action to be taken
Who will lead on the delivery of this action?
Identify milestones
Version 2 Cancer Dashboard MCCN 2010 17

5. Cancer incidence, cancer mortality
Cancer incidence
5a
Does the PCT review cancer incidence?
Level 1 The PCT has not completed baseline cancer incidence data
Level 2 Some evidence of recording cancer incidence emerging, but not for all the main
cancers
Level 3 Cancer incidence completed for all the main cancers. National and international
benchmarks completed
Level 4 Cancer incidence completed for all the main cancers. National and international
benchmarks completed The PCT has reviewed the cancers where the incidence
is increasing the most.
Level 5
Excellent
Self
assessment
rating
Cancer incidence completed for all the main cancers. National and international
benchmarks completed The PCT has reviewed the cancers where the incidence
is increasing the fastest. The PCT analyses cancer incidence rates versus other
factors such as survival and mortality.
Cancer mortality
5b
Does the PCT review cancer mortality?
Level 1 The PCT has not completed baseline cancer mortality data
Level 2 Some evidence of recording cancer mortality emerging, but not for all the main
cancers, bowel, lung, breast and prostate
Level 3 Cancer mortality completed for all the main cancers. National and international
benchmarks completed. PCT ambitious cancer mortality has been set.
Level 4 Cancer mortality completed for all the main cancers. National and international
benchmarks completed. PCT ambitious cancer mortality has been set. The PCT
has reviewed the cancers where the cancer mortality is the highest.
Level 5
Excellent
Self
assessment
rating
Cancer mortality completed for all the main cancers. National and international
benchmarks completed. PCT ambitious cancer mortality has been set. The PCT
has reviewed the cancers where the cancer mortality is the highest. Mortality
rates have been scoped for the over 75s
Version 2 Cancer Dashboard MCCN 2010 18

How will the PCT reduce cancer mortality?
Action to be taken
Who will lead on the delivery of this action?
Identify milestones
6. Survival
Cancer Survival
6a
Does the PCT review survival data?
Level 1 No evidence
Level 2 PCT receives regular survival reports for 5 year survival
Level 3 PCT receives regular survival reports for 5 year survival and analyses data
Level 4 PCT analyses some data and collects 1 and 5 year data. The PCT is involved in
1 and 5 year survival discussions network wide for less common cancer types
Level 5
Excellent
Self
assessment
rating
PCT uses data to analyse survival for all cancer. Collects 1 and 5 year survival
rates and compares results against international benchmarks. The PCT
understands 1 and 5 year survival data for less common cancer types
How will the PCT improve cancer survival?
Action to be taken
Who will lead on the delivery of this action?
Identify milestones
Version 2 Cancer Dashboard MCCN 2010 19

7. Inequalities
Cancer Inequalities
7a
Can the PCT identify specific groups where the cancer inequalities are the
greatest?
Level 1 No evidence
Level 2 The PCT can identify specific groups were inequalities are the greatest
Level 3 The PCT can provide data that shows inequalities for marginalized groups in
respect of cancer mortality, incidence and screening activity
Level 4 The PCT can provide data that shows inequalities for marginalized groups in
respect of cancer mortality, incidence and screening activity. Data intelligence
can be shared on groups described in the national cancer equality initiative. BME
communities, those with disabilities, age related inequalities, young people,
socio economic inequalities, people who are disadvantaged because of sexual
orientation
Level 5
Excellent
Self
assessment
rating
The PCT can provide data that shows inequalities for marginalized groups in
respect of cancer mortality, incidence and screening activity. Data intelligence
can be shared on groups described in the national cancer equality initiative. BME
communities, those with disabilities, age related inequalities, young people,
socio economic inequalities, people who are disadvantaged because of sexual
orientation. The PCT demonstrates interventions and outcomes to reduce
inequalities.
How will the PCT reduce cancer inequalities?
Action to be taken
Who will lead on the delivery of this action?
Identify milestones
Version 2 Cancer Dashboard MCCN 2010 20

8. Local Plans: Findings from local awareness and early detection initiative or strategy (LAEDI)
a. Summary of event
b. Key recommendations
Key issues discussed
Action to be taken
Who will lead on the delivery of this action?
9. Example of local initiatives
a. Community engagement
b. Service improvement
c. Reducing inequalities
Examples of local cancer action and initiatives?
Name of initiative (Describe the initiative, what was the outcome?)
Name of initiative (Describe the initiative, what was the outcome?)
Name of initiative (Describe the initiative, what was the outcome?)
Name of initiative (Describe the initiative, what was the outcome?)
Name of initiative (Describe the initiative, what was the outcome?)
Version 2 Cancer Dashboard MCCN 2010 21

10. Commissioning commitments- operating plan and strategic commissioning plans
Key cancer commissioning pledges
Summary of key cancer priorities
Other priorities identified
Version 2 Cancer Dashboard MCCN 2010 22

Cancer Performance summary table for xxx PCT
▲ ▲ ▲ ▲ ▲
Number Measure Level1 Level2 Level 3 Level 4 Level 5
1a Has the PCT conducted a CAM to benchmark local awareness? ▲
1b Has the PCT engaged the public in cancer awareness activity? ▲
2a Does the PCT have a screening operational and strategic lead in place? ▲
2b Does the PCT have an implementation plan for screening in place? ▲
2c Has the PCT made plans to start the extension of breast cancer screening offered to women ▲
aged 47-49 and 71-73 from April 2010?
2d Is the PCT reporting the results of cervical screening within two weeks? ▲
2e How is the PCT achieving the national average coverage rate for bowel screening? How is the
PCT improving coverage rates
▲
2f How is the PCT achieving the national average coverage rate breast screening? How is the
PCT improving coverage rates
▲
2g How is the PCT achieving the national average coverage rate for cervical screening? How is
the PCT improving coverage rates
▲
2h How is the PCT identifying which groups in the community are not participating in screening? ▲
3a The PCT can provide evidence of audits that inform the PCT of delays in the patient
experience prior to diagnosis using primary care audits
▲
3b The PCT regularly reviews urgent TWW activity The PCT regularly reviews urgent TWW
activity including did not attend (DNA) and cancellation rates
▲
3c The PCT regularly reviews TWW activity including yield rates ▲
3d The PCT can review cancers that have been diagnosed via accident and emergency ▲
4a How complete is staging data for cancers 3 months after registration? ▲
4b Is MDT performance improving? ▲
5a Does the PCT review cancer incidence? ▲
5b Does the PCT review cancer mortality? ▲
6a Does the PCT review survival data? ▲
7a Can the PCT identify specific groups where the cancer inequalities are the greatest? ▲